ITGB2 and pancreatic neoplasm: This indicates that MUC4 contributes resistance to chemotherapeutic agent gemcitabine in CD18/HPAF pancreatic cancer cells by activation of the MUC4-HER2-mediated anti-apoptotic pathway.